Development of microRNA-based therapy for pancreatic cancer

Despite extensive research efforts on diagnosis and treatment,pancreatic ductal adenocarcinoma(PDAC)remains a devastating disease and the third leading cause of cancer-related death in the United States.Resistance to current therapeutic approaches is a major reason for the poor survival of pancreatic patients.In order to overcome this major challenge and improve patient outcomes,we are in desperate need of novel therapeutic approaches.PDAC chemoresistance mechanisms are complex and multifaceted.Novel therapeutics must be equipped to deal with this challenge.microRNAs(miRNAs)have emerged as strong candidates to fill this role due to their multitargeted function.miRNAs have been shown to have important roles in pancreatic cancer resistance.In this review,we summarize the recent advancement in miRNA research related to PDAC therapeutic resistance mechanisms and the potential of miRNAs as therapeutic agents for future clinical management of PDAC.